NICEx

News

Alnylam's ATTR cardiomyopathy drug backed for NHS use

Patients with ATTR-CM in England and Wales will soon have a new treatment option, after NICE backed use of Alnylam's three-month injectable Amvuttra.

News

ViiV's bimonthly HIV PrEP jab cleared for use by NHS

ViiV's injectable HIV PrEP Apretude will soon be an alternative for people in England and Wales who cannot use daily oral options.

News

NICE finalises support for CSL's HAE therapy Andembry

CSL Behring's Andembry can be used to prevent recurrent attacks of HAE by the NHS, following finalised guidance from reimbursement authority NICE.

News

US and UK flags meet on a diagonal, with grey border line

AbbVie joins BMS in taking a hard line on UK drug pricing

AbbVie has said it may not launch its ovarian cancer therapy Elahere in the UK if a viable NHS price cannot be agreed with NICE.

News

NICE CEO to step down by year-end

Sam Roberts is stepping down from the role of NICE CEO to support her children through a difficult time, and a search for her replacement is underway.

News

UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer

AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo

Alnylam's ATTR cardiomyopathy drug backed for NHS use

ViiV's bimonthly HIV PrEP jab cleared for use by NHS

NICE finalises support for CSL's HAE therapy Andembry

AbbVie joins BMS in taking a hard line on UK drug pricing

NICE CEO to step down by year-end

UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

NICEx

Editor's Picks